Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

Better-than-expected economic news from China also supported stocks after the China March manufacturing PMI rose +0.3 to 50.5, better than expectations of 50.4 and the strongest report in a year. In ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

Fintel reports that on March 31, 2025, RBC Capital downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

RBC Capital analyst Brian Abrahams downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161. The ...

Mizuho Securities analyst Uy Ear maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...

Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...

The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, ...